Skip to main content

Invaryant and PatientMatters Announce Strategic Partnership

Technology innovator and patient payment and advocacy pioneer partner to enhance access for at-risk, underserved patients

ROSWELL, Ga. - May 22, 2020 - (Newswire.com)

​​​Invaryant, a patient-centric, healthcare-technology company enabling patients to collect and share their health data within families and care teams and access safe care anywhere, and PatientMatters, a patient access and advocacy solutions provider helping hospitals and health systems offer their patients personalized financial solutions, are pleased to announce they have entered into a strategic partnership.

The partnership leverages PatientMatters’s patient advocacy expertise with Invaryant’s patient-health-record technology to further enhance access for underserved and at-risk patients.

“We provide data to improve care, and PatientMatters helps patients access care,” said Ramon Dempers, Invaryant’s founder. “This partnership addresses disparities in care for underserved patients nationwide.”

The complementary nature of Invaryant and PatientMatters’ solutions provides an ideal opportunity to leverage each other’s strengths. Invaryant’s patent-pending technology, Invaryant Health Platform, automatically consolidates patient-health records to deliver comprehensive access to all healthcare stakeholders, including patients, providers, and clinical researchers. And with its proven 30-year track record, PatientMatters’s IntelliGuideTM Advocacy solution excels in improving the patient financial experience by advocating for uninsured and self-pay patients throughout their healthcare journey. Each organization, in their own right, is well-positioned for growth in today’s rapidly transforming healthcare industry.

“Our partnership with Invaryant enables us to share data insights relating to the patient journey, both from a financial and clinical viewpoint,” said David Shelton, CEO at PatientMatters. “This broad and comprehensive view into the patient journey across the entire healthcare system will help to power new technologies and services and expand our ability to enhance the patient experience for all.”

About Invaryant

Invaryant is a Georgia-based healthcare-technology company that is enabling safer healthcare through integrated, real-world-data technology. This unique platform connects and supports patients, healthcare providers, and clinical researchers. With AI and patent-pending technology, Invaryant will lead healthcare and life science into a new era of patient safety, access, and innovation. Founded in 2015 as a result of its founder losing a family member to a medical error, Invaryant is a passionate team that's reimagining healthcare to improve the lives of all people. To learn more visit invaryant.com or follow @invaryant.

About PatientMatters

PatientMatters brings compassion and consumerism to the financial experience of care, helping hospitals and health systems offer highly personalized financial solutions that improve satisfaction, cash flow, profitability, and outcomes. Based on decades of experience, the PatientMatters IntelliPass™ System brings together a comprehensive set of patient-payment and advocacy solutions, along with intelligent workflow-automation tools, to ensure every patient is satisfied and providers are appropriately compensated. PatientMatters serves over 130 hospital and health systems in over 350 locations across the country, providing cutting-edge technology, financial tools, and process-transformation services with staff training and support to help deliver a new level of consumer-friendly healthcare. To learn more, visit www.patientmatters.com.

Contacts:

Shawn Tolan

Chief Growth Officer, Invaryant

(770) 710-5679

shawn@invaryant.com

Kara McCrudden

Aria Marketing for PatientMatters

(617) 332-9999 x201

kmcrudden@ariamarketing.com




Press Release Service by Newswire.com

Original Source: Invaryant and PatientMatters Announce Strategic Partnership
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.